Standard

Optimization, characterization, and cytotoxicity studies of novel anti-tubercular agent-loaded liposomal vesicles. / Obiedallah, Manar; Mironov, Maxim; Belyaev, Danila и др.
в: Scientific Reports, Том 14, № 1, 524, 2024.

Результаты исследований: Вклад в журнал › Статья › Рецензирование

Harvard

Obiedallah, M, Mironov, M, Belyaev, D, Ene, A, Vakhrusheva, D, Krasnoborova, SY, Bershitsky, S, Shchepkin, D, Minin, A, Ishmetova, R, Ignatenko, N, Tolshchina, S, Fedorova, O & Rusinov, GL 2024, 'Optimization, characterization, and cytotoxicity studies of novel anti-tubercular agent-loaded liposomal vesicles', Scientific Reports, Том. 14, № 1, 524. https://doi.org/10.1038/s41598-023-49576-2

APA

Obiedallah, M., Mironov, M., Belyaev, D., Ene, A., Vakhrusheva, D., Krasnoborova, S. Y., Bershitsky, S., Shchepkin, D., Minin, A., Ishmetova, R., Ignatenko, N., Tolshchina, S., Fedorova, O., & Rusinov, G. L. (2024). Optimization, characterization, and cytotoxicity studies of novel anti-tubercular agent-loaded liposomal vesicles. Scientific Reports, 14(1), [524]. https://doi.org/10.1038/s41598-023-49576-2

Vancouver

Obiedallah M, Mironov M, Belyaev D, Ene A, Vakhrusheva D, Krasnoborova SY и др. Optimization, characterization, and cytotoxicity studies of novel anti-tubercular agent-loaded liposomal vesicles. Scientific Reports. 2024;14(1):524. doi: 10.1038/s41598-023-49576-2

Author

Obiedallah, Manar ; Mironov, Maxim ; Belyaev, Danila и др. / Optimization, characterization, and cytotoxicity studies of novel anti-tubercular agent-loaded liposomal vesicles. в: Scientific Reports. 2024 ; Том 14, № 1.

BibTeX

@article{b388499b69424792bf795102596f75ae,
title = "Optimization, characterization, and cytotoxicity studies of novel anti-tubercular agent-loaded liposomal vesicles",
abstract = "The treatment of tuberculosis is still a challenging process due to the widespread of pathogen strains resistant to antibacterial drugs, as well as the undesirable effects of anti-tuberculosis therapy. Hence, the development of safe and effective new anti-antitubercular agents, in addition to suitable nanocarrier systems, has become of utmost importance and necessity. Our research aims to develop liposomal vesicles that contain newly synthesized compounds with antimycobacterial action. The compound being studied is a derivative of imidazo-tetrazine named 3-(3,5-dimethylpyrazole-1-yl)-6-(isopropylthio) imidazo [1,2-b] [1,2,4,5] tetrazine compound. Several factors that affect liposomal characteristics were studied. The maximum encapsulation efficiency was 53.62 ± 0.09. The selected liposomal formulation T8* possessed a mean particle size of about 205.3 ± 3.94 nm with PDI 0.282, and zeta potential was + 36.37 ± 0.49 mv. The results of the in vitro release study indicated that the solubility of compound I was increased by its incorporation in liposomes. The free compound and liposomal preparation showed antimycobacterial activity against Mycobacterium tuberculosis H37Rv (ATCC 27294) at MIC value 0.94–1.88 μg/ml. We predict that the liposomes may be a good candidate for delivering new antitubercular drugs.",
author = "Manar Obiedallah and Maxim Mironov and Danila Belyaev and Antoaneta Ene and Diana Vakhrusheva and Krasnoborova, {Svetlana Yu.} and Sergey Bershitsky and Daniil Shchepkin and Artem Minin and Rashida Ishmetova and Nina Ignatenko and Svetlana Tolshchina and Olga Fedorova and Rusinov, {Gennady l.}",
note = "This research was funded by the Ministry of Science and Higher Education of the Russian Federation (Agreement on the provision of grants from the federal budget in the form of subsidies under paragraph 4 of Article 78.1 of the Budget Code of the Russian Federation, Moscow, 1 October 2020 No. 075-15-2020-777). Manar M. Obiedallah would like to acknowledge the partial financial support provided by the Egyptian Ministry of Higher Education and Scientific Research. The work of author AE was supported by Dunarea de Jos University of Galati, Romania.",
year = "2024",
doi = "10.1038/s41598-023-49576-2",
language = "English",
volume = "14",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - Optimization, characterization, and cytotoxicity studies of novel anti-tubercular agent-loaded liposomal vesicles

AU - Obiedallah, Manar

AU - Mironov, Maxim

AU - Belyaev, Danila

AU - Ene, Antoaneta

AU - Vakhrusheva, Diana

AU - Krasnoborova, Svetlana Yu.

AU - Bershitsky, Sergey

AU - Shchepkin, Daniil

AU - Minin, Artem

AU - Ishmetova, Rashida

AU - Ignatenko, Nina

AU - Tolshchina, Svetlana

AU - Fedorova, Olga

AU - Rusinov, Gennady l.

N1 - This research was funded by the Ministry of Science and Higher Education of the Russian Federation (Agreement on the provision of grants from the federal budget in the form of subsidies under paragraph 4 of Article 78.1 of the Budget Code of the Russian Federation, Moscow, 1 October 2020 No. 075-15-2020-777). Manar M. Obiedallah would like to acknowledge the partial financial support provided by the Egyptian Ministry of Higher Education and Scientific Research. The work of author AE was supported by Dunarea de Jos University of Galati, Romania.

PY - 2024

Y1 - 2024

N2 - The treatment of tuberculosis is still a challenging process due to the widespread of pathogen strains resistant to antibacterial drugs, as well as the undesirable effects of anti-tuberculosis therapy. Hence, the development of safe and effective new anti-antitubercular agents, in addition to suitable nanocarrier systems, has become of utmost importance and necessity. Our research aims to develop liposomal vesicles that contain newly synthesized compounds with antimycobacterial action. The compound being studied is a derivative of imidazo-tetrazine named 3-(3,5-dimethylpyrazole-1-yl)-6-(isopropylthio) imidazo [1,2-b] [1,2,4,5] tetrazine compound. Several factors that affect liposomal characteristics were studied. The maximum encapsulation efficiency was 53.62 ± 0.09. The selected liposomal formulation T8* possessed a mean particle size of about 205.3 ± 3.94 nm with PDI 0.282, and zeta potential was + 36.37 ± 0.49 mv. The results of the in vitro release study indicated that the solubility of compound I was increased by its incorporation in liposomes. The free compound and liposomal preparation showed antimycobacterial activity against Mycobacterium tuberculosis H37Rv (ATCC 27294) at MIC value 0.94–1.88 μg/ml. We predict that the liposomes may be a good candidate for delivering new antitubercular drugs.

AB - The treatment of tuberculosis is still a challenging process due to the widespread of pathogen strains resistant to antibacterial drugs, as well as the undesirable effects of anti-tuberculosis therapy. Hence, the development of safe and effective new anti-antitubercular agents, in addition to suitable nanocarrier systems, has become of utmost importance and necessity. Our research aims to develop liposomal vesicles that contain newly synthesized compounds with antimycobacterial action. The compound being studied is a derivative of imidazo-tetrazine named 3-(3,5-dimethylpyrazole-1-yl)-6-(isopropylthio) imidazo [1,2-b] [1,2,4,5] tetrazine compound. Several factors that affect liposomal characteristics were studied. The maximum encapsulation efficiency was 53.62 ± 0.09. The selected liposomal formulation T8* possessed a mean particle size of about 205.3 ± 3.94 nm with PDI 0.282, and zeta potential was + 36.37 ± 0.49 mv. The results of the in vitro release study indicated that the solubility of compound I was increased by its incorporation in liposomes. The free compound and liposomal preparation showed antimycobacterial activity against Mycobacterium tuberculosis H37Rv (ATCC 27294) at MIC value 0.94–1.88 μg/ml. We predict that the liposomes may be a good candidate for delivering new antitubercular drugs.

UR - http://www.scopus.com/inward/record.url?partnerID=8YFLogxK&scp=85181455194

UR - https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=tsmetrics&SrcApp=tsm_test&DestApp=WOS_CPL&DestLinkType=FullRecord&KeyUT=001136960700001

U2 - 10.1038/s41598-023-49576-2

DO - 10.1038/s41598-023-49576-2

M3 - Article

VL - 14

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 524

ER -

ID: 51655727